These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31953112)

  • 1. Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists.
    Alley L; Novak K; Havlin T; Irwin AN; Carson J; Johnston K; O'Kane N; Hartung DM
    Res Social Adm Pharm; 2020 Oct; 16(10):1422-1430. PubMed ID: 31953112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
    Irwin AN; Gray M; Ventricelli D; Boggis JS; Bratberg J; Floyd AS; Silcox J; Hartung DM; Green TC
    Res Social Adm Pharm; 2024 May; 20(5):512-519. PubMed ID: 38395644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
    Picco L; Lam T; Xia T; Nielsen S
    Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A randomised controlled factorial experiment.
    Picco L; Sanfilippo P; Xia T; Lam T; Nielsen S
    Int J Drug Policy; 2022 Nov; 109():103856. PubMed ID: 36150356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost.
    Upton C; Gernant SA; Rickles NM
    J Am Pharm Assoc (2003); 2020; 60(6):943-950. PubMed ID: 32792293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of Alberta pharmacists' attitudes, comfort and perceived barriers to a community-based naloxone program.
    Nowlan SE; MacKinnon NJ; Hincapie A; Tachuk M
    Can Pharm J (Ott); 2021; 154(4):262-270. PubMed ID: 34345319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacist Services in the Opioid Crisis: Current Practices and Scope in the United States.
    Thakur T; Frey M; Chewning B
    Pharmacy (Basel); 2019 Jun; 7(2):. PubMed ID: 31200469
    [No Abstract]   [Full Text] [Related]  

  • 13. Health-care practitioner use of prescription drug monitoring programs in clinical practice in Australia: A qualitative study.
    Hoppe D; George Liu C; Khalil H
    Drug Alcohol Rev; 2023 Nov; 42(7):1647-1657. PubMed ID: 37402606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
    J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances.
    Fendrich M; Bryan JK; Hooyer K
    Subst Use Misuse; 2018 Jul; 53(8):1324-1330. PubMed ID: 29297725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study.
    Nielsen S; Picco L; Kowalski M; Sanfilippo P; Wood P; Larney S; Bruno R; Ritter A
    Res Social Adm Pharm; 2020 Dec; 16(12):1694-1701. PubMed ID: 32273255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacist utilization of prescription opioid misuse interventions: Acceptability among pharmacists and patients.
    Riley TB; Alemagno S
    Res Social Adm Pharm; 2019 Aug; 15(8):986-991. PubMed ID: 30665825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of pharmacists' likelihood to query prescription drug monitoring program databases.
    Arnold A; Bentley JP; Patel A; Holmes E
    J Am Pharm Assoc (2003); 2021; 61(5):614-622.e3. PubMed ID: 33994328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Educating Pharmacists on a Prescription Drug Monitoring Program.
    Fleming ML; Phan Y; Ferries EA; Hatfield MD
    J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.